prostatic hyperplasia


Also found in: Dictionary, Thesaurus.
Related to prostatic hyperplasia: benign prostatic hyperplasia

prostatic hyperplasia

Increase in the size of the inner zone of the PROSTATE GLAND. This commonly occurs, for no obvious reason, in men over 50 and leads to interference with the outflow of urine. The condition is treated by PROSTATECTOMY.
References in periodicals archive ?
American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH) 2010: American Urological Association Education and Research, Inc;.
Difficulty urinating isn't always a sign of benign prostatic hyperplasia (BPH).
Drugs that work through adrenergic receptors, such as Hytrin and Cardura, for benign prostatic hyperplasia and hypertension, and Flomax for benign prostatic hyperplasia, have been marketed successfully for a number of years.
Complete report on H1 2015 pipeline review of Benign Prostatic Hyperplasia with 51 market data tables and 15 figures, spread across 133 pages is available at http://www.
The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study.
In addition to this newly issued patent Synaptic has 17 additional applications pending on its alpha adrenergic receptor and benign prostatic hyperplasia technology.
Global Markets Direct's, 'Benign Prostatic Hyperplasia - Pipeline Review, H2 2012', provides an overview of the Benign Prostatic Hyperplasia therapeutic pipeline.
AUA Guidelines on management of benign prostatic hyperplasia (2003).
The ThermaStent is the second stent device developed for Endocare's benign prostatic hyperplasia product line.
Fore Pharma's latest report 'Global Benign Prostatic Hyperplasia Drug Pipeline Capsule - 2012 Update' provides most up-to-date information on key Research and Development activities (R&D) in the global Benign Prostatic Hyperplasia market.
May 15, 2015 /PRNewswire/ -- PROCEPT BioRobotics, a clinical-stage medical device company, announced today the results of a Phase II study investigating the safety and feasibility of Aquablation, a minimally invasive water ablation therapy, for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).